POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R/R DLBCL): A Matching Adjusted Indirect Treatment Comparison (MAIC) | Publicación